Antipsychotic drugs : classification, pharmacology and long-term health effects / Mark L. Aguilar Editor.

Format:

Book

Contributor:

Aguilar, Mark L., editor.

Series:

Psychiatry- theory, applications, and treatments series.

Psychiatry - Theory, Applications and Treatments

Language:

English

Subjects (All):

Antipsychotic drugs.

Physical Description:

1 online resource (156 p.)

Place of Publication:

Hauppauge, New York : Nova Science Publishers, Inc., 2016.

Summary:

Antipsychotics are a class of psychiatric medications primarily used to manage psychosis symptoms, including delusions, hallucinations, or disordered thought. This book discusses the classification, pharmacology and long-term health effects of antipsychotic drugs. Chapter One provides definitions, boundaries, and misconceptions of treatment adherence in psychotic disorders. Chapter Two studies pharmacopore and metabolic disturbances of atypical antipsychotic drugs. Chapter Three reviews recent human and animal studies showing anti-inflammatory effects of existing antipsychotic drugs, emphasizes recent clinical trials with some antiinflammatory drugs including aspirin, celecoxib, minocycline, and N-acetylcysteine (NAC), and offers theoretic explanations for roles of neuroinflammation in schizophrenia. Chapter Four addresses the aetiology, associations and types of sexual problems in patients on long-term antipsychotic medications.

Contents:

ANTIPSYCHOTIC DRUGS CLASSIFICATION, PHARMACOLOGY AND LONG-TERM HEALTH EFFECTS ; ANTIPSYCHOTIC DRUGS CLASSIFICATION, PHARMACOLOGY AND LONG-TERM HEALTH EFFECTS ; CONTENTS ; PREFACE ; Chapter 1 LONG-ACTING ANTIPSYCHOTICS: THE FACTS AND THE MYTHS FROM SYMPTOMS MANAGEMENT TO TARGETED TREATMENT ; ABSTRACT ; INTRODUCTION ; 1. ADHERENCE TO TREATMENT IN MENTAL DISORDERS: DEFINITIONS, BOUNDARIES AND MISCONCEPTIONS ; 1.1. From Compliance to Adherence to Treatment ; 1.2. The Factors Affecting Adherence to Treatments in Somatic Diseases

1.3. Adherence to Treatment in Mental Disorders: From Low Insight to Recovery 2. HISTORICAL BACKGROUND ; 2.1. The Development of Long-Acting Antipsychotics in the 1960s Psychiatric Cultural Context ; 2.2. The Question of Polypharmacy vs. Monotherapy ; 2.3. An Overview of the Development of First Generation LAIs ; 3. LONG-ACTING FGAS: HISTORY, DEVELOPMENT AND PHARMACEUTICAL PROPERTIES ; 3.1. Fluphenazine Enanthate/Decanoate ; 3.2. Clopenthixol Enanthate and Zuclopenthixol Decanoate/Acetate ; 3.3. Flupenthixol Decanoate ; 3.4. Haloperidol/Bromperidol Decanoate

3.5. Pipothiazine Palmitate/Undecylenate 3.6. Fluspirilene/Penfluridol ; 3.7. Perphenazine Enanthate/Decanoate ; 3.8. Oxyprothepin Decanoate, the LAI that came in from the Cold; 4. THE CHALLENGE OF THE 'LAST RESORT' TREATMENTS: NEW TECHNOLOGIES FOR THE SECOND GENERATION LAIS ; 4.1. Risperidone Long-Acting Injection ; 4.3. Paliperidone Palmitate ; 4.4. Olanzapine Pamoate ; 4.5. Aripiprazole, Long-Acting Injectable Formulation ; 5. THE UTILIZATION OF LAIS: CLINICAL PRINCIPLES OF BEST TREATMENT PRACTICE

5.1. Support in the Community is Necessary to Tackle Non-Adherence to Treatments when Using LAIs 5.2. Practicioners' and Patients' Attitudes towards LAIs ; 5.3. The Treatment with LAIs might be Effectively Supported by Treatment Alliance and Effective Communication Strategies ; 5.4. More Benefits than Risks from the Treatment with Long-Acting Antipsychotics? ; 6. RESEARCH INDICATIONS ON LAIS: BEST EVIDENCE FROM REAL-WORLD PRACTICE ; 6.1. Introduction ; 6.2. Materials and Methods ; 6.2.1. The Catchment Area ; 6.2.2. Assessment of LAIs use in Portogruaro CMHC

6.2.3. Characteristics of the Sample 6.3. Results ; 6.4. Discussion and Conclusion ; 7. THE NEW EVIDENCE STEMMING FROM RESEARCH ; 7.1. Forthcoming Antipsychotic Injections and other Long-Acting Formulations for Integrated Mental Health Treatments ; 7.1.1. Iloperidone Long-Acting Injection ; 7.1.2. Transdermal Olanzapine Patches ; 7.1.3. Transdermal Risperidone Patches ; 7.1.4. Aripiprazole Long-Acting Oral Formulation ; 7.1.5. Paliperidone Three-Month Long-Acting Injection ; 7.2. Long-Acting Drugs for New or Unusual Context ; 7.2.1. LAIs and First-Episode Psychoses

7.2.2. LAIs and 'Multiproblematic' Users

Notes:

Description based upon print version of record.

Includes bibliographical references at the end of each chapters and index.

Description based on print version record.

ISBN:

1-63484-418-1